Maharashtra FDA suspends manufacturing at Sequent's Mahad unit

Maharashtra Food and Drug Administration (FDA) has ordered suspension of manufacturing at drug firm Sequent Scientific's Mahad facility for a period of 15 days, starting July 1.
In a regulatory filing, the company said after inspection, the FDA has passed an order to suspend manufacturing licences at Mahad unit for 15 days, from July 1 to July 15, 2016.
"All of the procedural matters have been addressed by the company, and as a process we have filed an appeal with the Minister of Health and Medical Education of Maharashtra for staying and subsequent revocation of this order," Sequent Scientific said.

The company is hopeful of getting the process completed in the next couple of days, it added.
In the meantime, the unit continues to operate and the company expects no business interruptions, it said.
Sequent shares were trading at Rs 140.75 apiece on the BSE, down 2.39 per cent from previous close.